Troglitazone (TGZ), a PPARG agonist, was reported to induce G2/M cell cycle arrest through activation of p38 mitogen-activated protein kinase in renal cell carcinoma [18, 19], and similar effects were also seen in bladder cancer cells [20]. This evidence concerns the gene MAPK14 and urinary bladder carcinoma.